Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Medicine|April 6, 2006
Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in ratsHitoshi Yoshiji, Shigeki Kuriyama, Ryuichi Noguchi, et al.
Thrombosis and Haemostasis|June 4, 2008
Comprehensive analysis of ADAMTS13 in patients with liver cirrhosisMasahito Uemura, Yoshihiro Fujimura, Masanori Matsumoto, et al.
International Journal of Molecular Medicine|October 4, 2007
Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in ratsKiyoshi Asada, Hitoshi Yoshiji, Ryuichi Noguchi, et al.
Oncology Reports|January 5, 2007
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activitiesKoji Yanase, Hitoshi Yoshiji, Yasuhide Ikenaka, et al.
Journal of Gastroenterology|March 26, 2009
Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic ratsHitoshi Yoshiji, Ryuichi Noguchi, Mitsuteru Kitade, et al.
Hepatology (Baltimore, Md.)|September 29, 2006
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in ratsMitsuteru Kitade, Hitoshi Yoshiji, Hideyuki Kojima, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 2, 2012
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease scoreHiroaki Takaya, Masahito Uemura, Yoshihiro Fujimura, et al.
Molecular Medicine Reports|April 12, 2011
Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitisMitsuteru Kitade, Hitoshi Yoshiji, Hideyuki Kojima, et al.
International Journal of Molecular Medicine|November 21, 2008
Impact of insulin resistance on the progression of chronic liver diseasesKosuke Kaji, Hitoshi Yoshiji, Mitsuteru Kitade, et al.
BMC Research Notes|May 7, 2009
Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the ratHitoshi Yoshiji, Ryuichi Noguchi, Yasuhide Ikenaka, et al.
Pageof 6